Lead Product(s): FR104
Therapeutic Area: Immunology Product Name: FR104
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
The patent covers novel dosing regimen of FR104 in Europe through 2036 for therapeutic applications in autoimmune diseases, inflammatory diseases, transplantation and graft-versus-host disease.